"Complejo Hospitalario Universitario A Coruna (CHUAC)"
Welcome,         Profile    Billing    Logout  
 2 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Campelo, Rosario García
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
NADIM-ADJUVANT, NCT04564157: New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy

Active, not recruiting
3
210
Europe
Carboplatin, Paraplatin, Paclitaxel, Taxol, Nivolumab, Opdivo
Fundación GECP
Non-Small Cell Lung Cancer, Adjuvant Chemotherapy
04/30
04/31
Replay, NCT03526887: Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC

Completed
2
77
Europe
Pembrolizumab, KEYTRUDA
Spanish Lung Cancer Group
Lung Cancer
12/22
03/23
ARIAN, NCT06431633: Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

Not yet recruiting
2
129
Europe
Zimberelimab, anti-PD-1 monoclonal antibody AB122, Sacituzumab govitecan, Trodelvy, Cisplatin, Platinol, Carboplatin, Paraplatin
Fundación GECP
Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma
11/31
11/31
GECP 20/01_Neo-DIANA, NCT04512430: Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Terminated
2
4
Europe
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Carboplatin, Paraplatin, Pemetrexed, Alimta
Fundación GECP
Non Small Cell Lung Cancer, EGFR Gene Mutation
07/24
07/24
BIMES, NCT05005429 / 2020-004902-67: Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma

Completed
2
47
Europe
Bintrafusp alfa, M7824
Fundación GECP
Mesothelioma; Lung
02/24
02/24
RAISE, NCT05718323: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Recruiting
2
44
Europe
Niraparib
ETOP IBCSG Partners Foundation, GlaxoSmithKline, Development Limited
SCLC,Extensive Stage, SLFN11-positive
05/25
10/25
ADEPPT, NCT05673187 / 2022-002736-31: Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

Recruiting
2
68
Europe
Adagrasib
ETOP IBCSG Partners Foundation, Mirati Therapeutics Inc.
NSCLC Stage IV, KRAS P.G12C
10/25
03/26
NIVIPI-Brain, NCT05012254: Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

Active, not recruiting
2
71
Europe
Ipilimumab, Yervoy, Nivolumab, Opdivo, Carboplatin, Paraplatin, Cisplatin, Cis-diamminedichloroplatinum, Platinol, Paclitaxel, Taxol, Pemetrexed, Pemetrexed disodium; ALIMTA
Fundación GECP
Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer
03/26
12/26
PEERS, NCT05384015: Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

Recruiting
2
85
Europe
Lenvatinib, LENVIMA, KISPLYX, Pembrolizumab, KEYTRUDA, Etoposide, Etoposide Tevagen, Carboplatin, Carboplatin Accord
Fundación GECP
Small Cell Lung Cancer Extensive Stage
07/26
07/27
APOLO, NCT04776447 / 2020-004459-33: Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy.

Active, not recruiting
2
38
Europe
Carboplatin, Carboplatinum, Placlitaxel, Taxol, Atezolizumab, Tecentriq
Fundación GECP
Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Respiratory Tract Neoplasms, Carcinoma Bronchiogenic Stage III, Thoracic Neoplasms
11/26
11/27
MERIT-lung, NCT05398094: Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

Recruiting
2
43
Europe
Sotorasib, AMG510
Fundación GECP
Non-small Cell Lung Cancer Stage III, KRAS P.G12C
12/27
12/28
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
HDM-PMP22, NCT06590506: High Definition Medicine for Solid Tumors Oncology

Recruiting
N/A
300
Europe
Wearable, Vivosmart Garmin bracelet
Centro Nacional de Investigaciones Oncologicas CARLOS III
Metastatic Solid Tumor, Advanced Cancer
01/26
01/28
LUDICAS, NCT06018376: Characteristics of Sexual Dysfunction in Patients With Lung Cancer

Completed
N/A
553
Europe, RoW
Systemic oncological treatment, chemotherapy, radiotherapy
Fundación GECP
Lung Cancer, Sexual Dysfunction
02/24
02/24
SIENNA, NCT06634199: Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Not yet recruiting
N/A
50
Europe
Durvalumab, Imfinzi
Fundación GECP
Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation
11/27
11/27
NCT02941458: Thoracic Tumours Register

Recruiting
N/A
10000
Europe
Spanish Lung Cancer Group
Thoracic Tumors
12/25
12/30

Download Options